Lee's Pharmaceutical Holdings Limited (0950.HK) HKSE

Currency In HKD

AD

Lee's Pharmaceutical Holdings Limited

Address

Building 20E

Sha Tin,

China

Phone

852 2314 1282

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Employees

1022

First IPO Date

July 15, 2002

Key Executives

NameTitlePayYear Born
Xiaoyi LiFounder, Senior Adviser & Non-Executive Director8.16M1963
Siu Fong LeeChairman & Compliance Officer15.6M1957
Wanee LeelalertsuphakunMD, Chief Marketing & Sales Officer and Executive Director16.59M1954
Tsui Victor KailokGroup Chief Manufacturing Officer01967
Yiu Ming ChowGroup Chief Financial Officer & Company Secretary01973
Yuanjue SunChief Medical Officer0N/A
Yueshen ChenDirector of Administration in China01959
Ling FangCorporate Culture and Public Relations Director01969
Zhongyu JiaoGroup Deputy GM & GM of the Risk Control Centre01970
AD

Description

Established in 1994 and headquartered in Sha Tin, Hong Kong, Lee's Pharmaceutical Holdings Limited functions as an investment holding enterprise primarily engaged in the development, production, promotion, and sale of pharmaceutical goods, with a strong emphasis on the People's Republic of China market. The company's therapeutic scope covers a broad array of medical conditions, encompassing cardiovascular ailments, women's and children's health, rare disorders, cancer treatment, dermatological issues, obstetric care, and urological conditions. The business is structured into two main operational units: 1. Proprietary and Generic Products: This division focuses on manufacturing and marketing both its own innovative drugs and established generic formulations. Notable products include Livaracine for blood clot treatment, Yallaferon for viral infections, Slounase for managing bleeding, Eyprotor for corneal ulcers, Treprostinil injection for pulmonary hypertension, fondaparinux sodium injection for deep vein thrombosis, and Sodium Phenylbutyrate Granules for urea cycle disorders. 2. Licensed-In Products: This segment is dedicated to the distribution of pharmaceutical products acquired via licensing arrangements. Its comprehensive portfolio offers treatments such as Carnitene and Levocarnitine oral solution for carnitine deficiencies; Aloxi and Sancuso to combat chemotherapy-induced nausea and vomiting; Bredinin for immunosuppression in kidney transplant patients; Centraxal Plus for acute otitis media; Episil for alleviating oral mucositis pain; Ferplex for iron deficiency anemia; Gaslon N for gastric ulcers and gastritis; Intrarosa for vulvovaginal atrophy; Mictonorm for urinary incontinence; Natulan for certain stages of Hodgkin's disease; Omacor, an Omega-3-acid ethyl esters product; Zanidip and Rasilez for managing high blood pressure; Readyfusor for post-surgical pain management; Teglutik for Amyotrophic Lateral Sclerosis; Trittico for insomnia and depression; Unidrox for urinary and respiratory tract infections; probiotic offerings Dicoflor and VSL#3; and Zingo for topical localized pain relief.

AD